Pivotal trials comparing direct oral anticoagulants (DOACs) against warfarin in patients with
atrial fibrillation (AF) predominantly involved patients with high stroke risk. This study aimed …

Background In patients with non‐valvular atrial fibrillation (AF), direct‐acting oral
anticoagulants (DOACs) are at least non‐inferior to warfarin for the prevention of stroke and …

Introduction Atrial fibrillation (AF) is known as one of the independent risk factors for stroke
and might significantly increase its risk. Nowadays, direct-acting oral anticoagulants …

Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …

Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke
prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial …

Background: The current status and outcomes of direct oral anticoagulant (DOAC) use have
not been widely evaluated in unselected patients with atrial fibrillation (AF) in the real world …

Background Several observational studies have shown that the inappropriate dosing use of
direct oral anticoagulants (DOACs) in atrial fibrillation (AF) that does not conform to …

Introduction Outcomes associated with suboptimal use of antithrombotic treatments
(antiplatelets, warfarin, direct oral anticoagulants [DOACs]) are unclear in Chinese patients …

Background: Direct oral anticoagulants (DOACs) have been found to be similar or superior
to warfarin in reducing ischemic stroke and intracranial hemorrhage (ICH) in patients with …

Background There are no head-to-head randomized controlled trials comparing different
direct oral anticoagulants (DOACs). Thus, we systematically reviewed and meta-analyzed …